DNA prime-protein boost strategies protect cattle from bovine viral diarrhea virus type 2 challenge

Journal of General Virology

Volumn 89, Issue 2, 2008, Pages 453-466

  Liang, R ^a   van den Hurk, J V ^a   Landi, A ^a   Lawman, Z ^a   Deregt, D ^b   Townsend, H ^a   Babiuk, L A ^a   van Drunen Littel van den Hurk, Sylvia ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b CANADIAN FOOD INSPECTION AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE DIARRHEA VIRUS VACCINE; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; GLYCOPROTEIN E2; VIRUS ANTIBODY; VIRUS VACCINE; GP53, BOVINE VIRAL DIARRHEA VIRUS; PRIMER DNA; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS ENVELOPE PROTEIN;

ARTICLE; BODY TEMPERATURE; BOVINE DIARRHEA VIRUS; BOVINE DIARRHEA VIRUS TYPE 2; CALF (BOVINE); CATTLE DISEASE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; HUMORAL IMMUNITY; INTERFERON PRODUCTION; LEUKOPENIA; NONHUMAN; PRIORITY JOURNAL; VIRUS STRAIN; WEIGHT REDUCTION; ANIMAL; ANIMAL DISEASE; BLOOD; CATTLE; CHEMISTRY; GENETICS; IMMUNOLOGY; PLASMID; VACCINATION;

ANIMALIA; BOS; BOVINE VIRAL DIARRHEA VIRUS 1; BOVINE VIRAL DIARRHEA VIRUS 2; BOVINE VIRAL DIARRHEA VIRUS TYPE 2;

ANIMALS; ANTIBODIES, VIRAL; BOVINE VIRUS DIARRHEA-MUCOSAL DISEASE; CATTLE; DIARRHEA VIRUS 2, BOVINE VIRAL; DIARRHEA VIRUSES, BOVINE VIRAL; DNA PRIMERS; DNA, VIRAL; PLASMIDS; VACCINATION; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 41649097447     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.83251-0     Document Type: Article

References (58)

1. Anson, D. S. (2004). The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery. Genet Vaccines Ther 2, 9.
2. Baker, J. C. (1995). The clinical manifestations of bovine viral diarrhea infection. Vet Clin North Am Food Anim Pract 11, 425-445.
3. Barnett, S. W., Rajasekar, S., Legg, H., Doe, B., Fuller, D. H., Haynes, J. R., Walker, C. M. & Steimer, K. S. (1997). Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine 15, 869-873.
4. Bolin, S. R. & Ridpath, J. F. (1992). Differences in virulence between two noncytopathic bovine viral diarrhea viruses in calves. Am J Vet Res 53, 2157-2163.
5. Bolin, S. R. & Ridpath, J. F. (1998). Prevalence of bovine viral diarrhea virus genotypes and antibody against those viral genotypes in fetal bovine serum. J Vet Diagn Invest 10, 135-139.
6. Braun, R., Babluk, L. A. & van Drunen Littel-van den Hurk, S. (1998). Compatibility of plasmids expressing different antigens in a single DNA vaccine formulation. J Gen Virol 79, 2965-2970.
7. Brownile, J., Clarke, M. C., Hooper, L. B. & Bell, G. D. (1995). Protection of the bovine fetus from bovine viral diarrhoea virus by means of a new inactivated vaccine. Vet Rec 137, 58-62.
8. Canal, C. W., Strasser, M., Hertig, C., Masuda, A. & Peterhans, E. (1998). Detection of antibodies to bovine viral diarrhoea virus (BVDV) and characterization of genomes of BVDV from Brazil. Vet Microbiol 63, 85-97.
9. Cardoso, A. I., Sixt, N., Vallier, A., Fayolle, J., Buckland, R. & Wild, T. F. (1998). Measles virus DNA vaccination: antibody isotype is determined by the method of immunization and by the nature of both the antigen and the coimmunized antigen. J Virol 72, 2516-2518.
10. Collett M. S., Larson, R., Belzer, S. K. & Retzel, E. (1988). Proteins encoded by bovine viral diarrhea virus: the genomic organization of a pestivirus. Virology 165, 200-208.
11. Collett, M. S., Wiskerchen, M., Welniak, E. & Belzer, S. K. (1991). Bovine viral diarrhea virus genomic organization. Arch Virol Suppl 3, 19-27.
12. Couvreur, B., Letellier, C., Collard, A., Quenon, P., Dehan, P., Hamers, C., Pastoret P. P. & Kerkhofs, P. (2002). Genetic and antigenic variability in bovine viral diarrhea virus (BVDV) isolates from Belgium. Virus Res 85, 17-28.
13. Dean, H. J. & Leyh, R. (1999). Cross-protective efficacy of a bovine viral diarrhea virus (BVDV) type 1 vaccine against BVDV type 2 challenge. Vaccine 17, 1117-1124.
14. Dunachie, S. J., Walther, M., Vuola, J. M., Webster, D. P., Keating, S. M., Berthoud, T., Andrews, L, Bejon, P., Poulton, L & other authors (2006). A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine 24, 2850-2859.
15. Ellis, J., West, K., Cortese, V., Konoby, C. & Weigel, D. (2001). Effect of maternal antibodies on induction and persistence of vaccine- induced immune responses against bovine viral diarrhea virus type II in young calves. J Am Vet Med Assoc 219, 351-356.
16. Ellsworth, M. A., Fairbanks, K. K., Behan, S. Jackson, J. A., Goodyear, M., Oien, N. L., Meinert, T. R., & Leyh, R. D. (2006). Fetal protection following exposure to calves persistently infected with bovine viral diarrhea virus type 2 sixteen months after primary vaccination of the dams. Vet Ther 7, 295-304.
17. Evermann, J. F. & Ridpath, J. F. (2002). CJinical and epidemiologic observations of bovine viral diarrhea virus in the northwestern United States. Vet Microbiol 89, 129-139.
18. Fairbanks, K. K, Rinehart. C. L., Ohnesorge, W. C., Loughin, M. M. & Chase, C. C. (2004). Evaluation of fetal protection against experimental infection with type 1 and type 2 bovine viral diarrhea virus after vaccination of the dam with a bivalent modified-live virus vaccine. J Am Vet Med Assoc 225, 1898-1904.
19. Ficken, M. D., Ellsworth, M. A. & Tucker, C. M. (2006a). Evaluation of the efficacy of a modified-live combination vaccine against bovine viral diarrhea virus types 1 and 2 challenge exposures in a one-year duration-of-immunity fetal protection study. Vet Ther 7, 283-294.
20. Ficken, M. D., Ellsworth, M. A., Tucker. C. M. & Cortese, V. S. (2006b). Effects of modified-live bovine viral diarrhea virus vaccines containing either type 1 or types 1 and 2 BVDV on heifers and their offsprifig after challenge with noncytopathic type 2 BVDV during gestation. J Am Vet Med Assoc 228, 1559-1564.
21. Fulton, R. W. & Burge, L. J. (2000). Bovine viral diarrhea virus types 1 and 2 antibody response in calves receiving modified live virus or inactivated vaccines. Vaccine 19, 264-274.
22. Fulton, R. W., Johnson, B. J., Briggs, R. E., Ridpath, J. F., Saliki, J. T., Confer, A. W., Surge, L. J., Step, D. L., Walker, D. A. & Payton, M. E. (2006). Challenge with bovine viral diarrhea virus by exposure to persistently infected calves: protection by vaccination and negative results of antigen testing in nonvaccinated acutely infected calves. Can J Vet Res 70, 121-127.
23. Galloway, D., Liner, A., Legutki, J., Mateczun, A., Barnewall, R. & Estep, J. (2004). Genetic immunization against anthrax. Vaccine 22, 1604-1608.
24. Hamers, C., Couvreur, B., Dehan, P., Letellier, C., Fischer, L., Brun, A. J., Lewalle, P., Michaux, C., Pastoret P. P. & Kerkhofs, P. (2003). Assessment of the clinical and virological protection provided by a commercial inactivated bovine viral diarrhoea virus genotype 1 vaccine against a BVDV genotype 2 challenge. Vet Rec 153, 236-240.
25. Houe, H. (1995). Epidemiology of bovine viral diarrhea virus. Vet Clin North Am Food Anim Pract 11, 521-547.
26. Kim, I. J., Hyun, B. H., Shin, J. H., Lee, K. K., Lee, K. W., Cho, K. O. & Kang, M. I. (2006). Identificatiou of bovine viral diarrhea virus type 2 in Korean native goal (Capra hircus). Virus Res 121, 103-106.
27. Kong, W. P., Huang, Y., Yang, Z. Y., Chakrabarti, B. K., Moodie, Z. & Nabel, G. J. (2003). Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol 77, 12764-12772.
28. Konishi, E., Kosugi, S. & Imoto, J. (2006). Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 24, 2200-2207.
29. Kovacs, F., Magyar, T., Rinehart C., Obers, K., Schlesinger, K. & Ohnesorge, W. C. (2003). The live attenuated bovine viral diarrhea virus components of a multi-valent vaccine confer protection against fetal infection. Vet Microbiol 96, 117-131.
30. Li, Z., Zhang, H., Fan, X., Zhang, Y., Huang, J., Liu, Q., Tielle, T. E., Mathiesen, I., Kjeken, R. & Xiong, S. (2006). DNA electroporation prime and protein boost strategy enhances humoral immunity of tuberculosis DNA vaccines in mice and non-human primates. Vaccine 24, 4565-4568.
31. Liang, R., van den Hurk, J. V., Zheng, C., Yu, H., Pontarollo, R. A., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. (2005). Immunization with plasmid DNA encoding a truncated, secreted form of the bovine viral diarrhea virus E2 protein elicits strong humoral and cellular immune responses. Vaccine 23, 5252-5262.
32. Liang, R., van den Hurk, J. V., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. (2006). Priming with DNA encoding E2 and boosting with E2 protein formulated with CpG oligodeoxynucleotides induces strong immune responses and protection from bovine viral diarrhea virus in cattle. J Gen Virol 87, 2971-2982.
33. Lu, S. (2006). Combination DNA plus protein HIV vaccines. Springer Semin Immunopathol 28, 255-265.
34. Martin, J. E., Sullivan, N. J., Enama, M. E., Gordon, I. J., Roederer, M., Koup, R. A., Bailer, R. T., Chakrabarti, B. K., Bailey, M. A. & other authors (2006). A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 13, 1267-1277.
35. McConkey, S. J., Reece, W. H., Moorthy, V. S., Webster, D., Dunachie, S., Butcher, G., Vuola, J. M., Blanchard, T. J., Gothard, P. & other authors (2003). Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9, 729-735.
36. Moore, Q. C., Bosarge, J. R., Quin, L. R. & McDaniel, L. S. (2006). Enhanced protective immunity against pneumococcal infection with PspA DNA and protein. Vaccine 24, 5755-5761.
37. Mwau, M., Cebere, I., Sutton, J., Chikoti, P., Winstone, N., Wee, E. G., Beattie, T., Chen, Y. H., Dorrell, L & other authors (2004). A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 85, 911-919.
38. Nakamura, Y., Gojobori, T. & Ikemura, T. (2000). Codon usage tabulated from international DNA sequence databases: status for the year 2000. Nucleic Acids Res 28, 292.
39. O'Hagan, D. T., Singh, M. & Ulmer, J. B. (2006). Microparticle-based technologies for vaccines. Methods 40, 10-19.
40. Pal, R., Kalyanaraman, V. S., Nair, B. C.. Whitney, S., Keen, T., Hocker, L., Hudacik, L., Rose, N., Mboudjeka, I. & other authors (2006). Immunization of rhesus macaques with a polyvalent DNA prime/ protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immuno-deficiency virus of R5 phenotype. Virology 348, 341-353.
41. Pellerin, C., van den Hurk, J., Lecomte, J. & Tussen, P. (1994). Identification of a new group of bovine viral diarrhea virus strains associated with severe outbreaks and high mortalities. Virology 203, 260-268.
42. Pratelli, A., Martella, V., Cirone, F., Buonavoglia, D., Elia, G., Tempesta, M. & Buonavoglia, C. (2001). Genomic characterization of pestiviruses isolated from lambs and kids in southern Italy. J Virol Methods 94, 81-85.
43. Raggo, C., Habermehl, M., Babiuk, L. A. & Griebel, P. (2000). The in vivo effects of recombinant bovine herpesvirus-1 expressing bovine interferon-γ. J Gen Virol 81, 2665-2673.
44. Reber, A. J., Tanner, M., Okinaga, T., Woolums, A. R., Williams, S., Ensley, D. T. & Hurley, D. J. (2006). Evaluation of multiple immune parameters after vaccination with modified live or killed bovine viral diarrhea virus vaccines. Comp Immunol Microbiol Infect Dis 29, 61-77.
45. Ridpath, J. F. (2005). Practical significance of heterogeneity among BVDV strains: impact of biotype and genotype on US control programs. Prev Vet Med 72, 17-30 (discussion 215-219).
46. Ridpath, J. F., Bolin, S. R. & Dubovi, E. J. (1994). Segregation of bovine viral diarrhea virus into genotypes. Virology 205, 66-74.
47. Sedegah, M., Charoenvit, Y., Minh, L., Belmonte, M., Majam, V. F., Abot, S., Ganeshan, H., Kumar, S., Bacon, D. J. & other authors (2004). Reduced immunogenicity of DNA vaccine plasmids in mixtures. Gene Ther 11, 448-456.
48. Shimazaki, T., Sekiguchi, H., Nakamura, S., Taguchi, K., Inoue, Y. & Satoh, M. (1998). Segregation of bovine viral diarrhea virus isolated in Japan into genotypes. J Vet Med Sci 60, 579-583.
49. Shiver, J. W., Fu, T. M., Chen, L., Casimiro, D. R., Davies, M. E., Evans, R. K., Zhang, Z. O., Simon, A. J., Trigona, W. L. & other authors (2002). Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335.
50. van Oirschot, J. T., Bruschke, C. J. & van Rijn, P. A. (1999). Vaccination of cattle against bovine viral diarrhoea. Vet Microbiol 64, 169-183.
51. Vilcek S., Paton, D. J., Durkovic, B., Strojny, L., Ibata, G., Moussa, A., Loitsch, A., Rossmanith, W., Vega, S. & other authors (2001). Bovine viral diarrhoea virus genotype 1 can be separated into at least eleven genetic groups. Arch Virol 146, 99-115.
52. Vilcek, S., Greiser-Wilke, I., Durkovic, B., Obritzhauser, W., Deutz, A. & Kofer, J. (2003). Genetic diversity of recent bovine viral diarrhoea viruses from the southeast of Austria (Styria). Vet Microbiol 91, 285-291.
53. Vilcek, S., Durkovic, B., Kolesarova, M. & Paton, D. J. (2005). Genetic diversity of BVDV: consequences for classification and molecular epidemiology. Prev Vet Med 72, 31-35 (discussion 215-219).
54. Wakeley, P. R., Turner, J. L., Ibate, G., King, D. P., Sandvik, T., Howard, P. & Drew, T. W. (2004). Characterisation of a type 2 bovine viral diarrhoea virus isolated from cattle in the UK. Vet Microbiol 102, 19-24.
55. Waldvogel, A. S., Hediger-Weithaler, B. M., Eicher, R., Zakher, A., Zarlenga, D. S., Gasbarre, L. C. & Heussler, V. T. (2000) Interferon-γ and interleukin-4 mRNA expression by peripheral blood mononuclear cells from pregnant and non-pregnant cattle seropositive for bovine viral diarrhea virus. Vet Immunol Immunopathol 77, 201-212.
56. Webster, D. P., Dunachie, S., McConkey, S., Poulton, I., Moore, A. C., Walther, M., Laidlaw, S. M., Peto, T., Skinner, M. A. & other authors (2006). Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 24, 3026-3034.
57. Wolfmeyer, A., Wolf, G., Beer, M., Strube, W., Hehnen, H. R., Schmeer, N. & Kaaden, O. R. (1997). Genomic (5′UTR) and serological differences among German BVDV field isolates. Arch Virol 142, 2049-2057.
58. Yu, H., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. (2004). Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3. J Gen Virol 85, 1533-1543.